Hims & Hers Health (HIMS) represents a high-conviction "Big Tech" style opportunity in telehealth, currently trading at an attractive valuation of ~$26 following a significant $1 million insider buy. Investors should look for a major revenue catalyst as the company integrates its Eucalyptus acquisition, which is expected to add up to $300M in international revenue not yet reflected in official guidance. The company is aggressively expanding into the weight-loss market by offering generic GLP-1s at $149, forcing incumbents like Novo Nordisk (NVO) to lower prices to compete. Beyond weight loss, HIMS is positioned to lead the longevity medicine sector by launching 12 FDA-approved peptides and expanding into sleep and health-tracking bundles. With a long-term revenue target of $6.5 billion by 2030 and 70%+ gross margins, this stock is a top pick for a subscription-based healthcare compounder.

Hims & Hers Health, Inc. (HIMS)

• HIMS is described as a "steady, long-term, top-line compounder" that is currently undervalued despite a recent 9% weekly rebound. • Insider Activity: A recent $1 million insider buy has significantly boosted market sentiment. • Financial Health: * Growth: Predicted top-line revenue growth of 30%+. * Margins: Excellent gross margins at 70%+; the company is currently EBITDA profitable. * Valuation: Trading at an EV/GP/RG (Enterprise Value over Gross Profit over Revenue Growth) of 0.109, which the analyst considers "dirt cheap." * Guidance: Management has guided for $6.5 billion in revenue by 2030, nearly tripling current revenue of $2.3 billion. • Market Position: The company holds approximately 50% of the telehealth market, competing against LifeMD, Roe, and Noom. • International Expansion: Revenue from international markets is expected to 10X. The recent Eucalyptus acquisition (Australia/Japan/UK) is a major driver not yet fully reflected in official guidance. • Product Innovation: * Peptides: HIMS owns the CS Bio manufacturing facility and is positioned to launch 12 FDA-approved peptides. * Longevity & Sleep: New focus areas for future product launches. * GLP-1s (Weight Loss): In Canada, HIMS is offering generic semaglutide for $149 CAD, matching Novo Nordisk’s coupon pricing.

Takeaways

• "Big Tech" Potential: The analyst views HIMS not as a traditional healthcare company, but as a future "Big Tech" entity similar to Spotify or Netflix due to its subscription-based model and category dominance. • Sandbagged Guidance: There is a strong belief that 2026 guidance is conservative ("sandbagged") because it excludes the Eucalyptus acquisition, which brings ~$450M in ARR (Annual Recurring Revenue). • Subscription Evolution: Under the leadership of Deidre (formerly of Robinhood), HIMS is attempting to turn its subscription into a "no-brainer" bundle (similar to Robinhood Gold), potentially adding third-party benefits like Stelo or PreNuvo. • Investment Thesis: The stock is viewed as a "Steady Eddy" compounder that has grown through earned revenue rather than multiple expansion, offering a significant margin of safety at current prices (~$26).

Novo Nordisk (NVO) & Eli Lilly (LLY)

• Mentioned in the context of the competitive landscape for GLP-1 (weight loss) medications. • Novo Nordisk recently lowered prices in Canada to $149/month to compete with generic/compounded alternatives.

Takeaways

• Pricing Wars: The entry of HIMS into the GLP-1 space is forcing traditional pharmaceutical giants to lower prices or offer aggressive coupons to maintain market share. • Strategic Partnership: The analyst suggests HIMS is pursuing a "friendship" or partnership model with these giants rather than a purely litigious one, which may be more valuable for long-term stability.

Eucalyptus (Private Acquisition)

• A major international telehealth player recently acquired by HIMS. • Operates in Australia, Japan, and Europe.

Takeaways

• Accretive Growth: The acquisition was reportedly made "on the cheap" with seller financing. • Revenue Impact: Expected to add $250M–$300M in revenue in the second half of the year, providing a significant catalyst for a guidance raise.

Investment Themes & Sectors

Telehealth & Compounding

• The industry is shifting away from traditional insurance models toward direct-to-consumer (DTC) subscriptions. • Compounding medications are highlighted as a key tool for "breaking the price" of expensive branded drugs, making healthcare more accessible.

Longevity Medicine

• Identified as the "future of medicine." HIMS is actively positioning itself to lead in this sector through peptide therapy and specialized health tracking.

Subscription-Based Healthcare

• The "Amazon Prime-ification" of healthcare. The goal is to create a subscription so valuable (through discounts, access, and bundled services) that consumers maintain it even when they are "super healthy."